ID   KTCTL-21
AC   CVCL_5868
SY   KTCTL21; RCC-AB; RCCAB
DR   ArrayExpress; E-MTAB-3610
DR   cancercelllines; CVCL_5868
DR   Cell_Model_Passport; SIDM00821
DR   CLS; 300247
DR   Cosmic; 1352059
DR   Cosmic; 1751970
DR   Cosmic-CLP; 1524418
DR   DepMap; ACH-002187
DR   EGA; EGAS00001000978
DR   GDSC; 1524418
DR   GEO; GSM1670360
DR   PharmacoDB; RCCAB_1287_2019
DR   PRIDE; PXD030304
DR   Wikidata; Q54900641
RX   PubMed=8086765;
RX   PubMed=27397505;
RX   PubMed=28489074;
RX   PubMed=30894373;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Population: Caucasian.
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Genome ancestry: African=0%; Native American=0.07%; East Asian, North=0.03%; East Asian, South=0%; South Asian=1.41%; European, North=62.87%; European, South=35.62% (PubMed=30894373).
CC   Discontinued: CLS; 300247; true.
ST   Source(s): CLS; Cosmic-CLP
ST   Amelogenin: X,Y
ST   CSF1PO: 10,13
ST   D13S317: 12,13
ST   D16S539: 11
ST   D18S51: 15
ST   D21S11: 30,33.2
ST   D3S1358: 17
ST   D5S818: 11,12
ST   D7S820: 9,11
ST   D8S1179: 12,15
ST   FGA: 22,25
ST   Penta D: 10,12
ST   Penta E: 7
ST   TH01: 7,9.3
ST   TPOX: 8,11
ST   vWA: 15,19
DI   NCIt; C4033; Clear cell renal cell carcinoma
DI   ORDO; Orphanet_319276; Clear cell renal carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   49Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 24
//
RX   PubMed=8086765; DOI=10.1007/BF00252823;
RA   Gross A.J., Wolff M., Fandrey J., Miersch W.-D., Dieckmann K.-P.,
RA   Jelkmann W.;
RT   "Prevalence of paraneoplastic erythropoietin production by renal cell
RT   carcinomas.";
RL   Clin. Investig. 72:337-340(1994).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=28489074; DOI=10.1038/ncomms15165;
RA   Sinha R., Winer A.G., Chevinsky M., Jakubowski C., Chen Y.-B., Dong Y.-Y.,
RA   Tickoo S.K., Reuter V.E., Russo P., Coleman J.A., Sander C.,
RA   Hsieh J.J.-D., Hakimi A.A.;
RT   "Analysis of renal cancer cell lines from two major resources enables
RT   genomics-guided cell line selection.";
RL   Nat. Commun. 8:15165.1-15165.10(2017).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//